Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex Corp.

Division of Amgen Inc.
www.immunex.com

Latest From Immunex Corp.

Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit

The FDA has approved Samsung Bioepis’ Eticovo as the second biosimilar competitor to Amgen’s blockbuster rheumatoid arthritis biologic Enbrel. Amgen immediately sued for patent infringement.

Regulation Legal Issues

Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

Although Samsung has not provided 180-day advance notice of commercialization for Eticovo, its recently approved biosimilar to Enbrel, Amgen seeks a preliminary injunction because it has reason to believe the company is prepared to launch ‘imminently.’

Biosimilars Legal Issues

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Sandoz's request that US FDA remove psoriatic arthritis and plaque psoriasis indications from biosimilar's approved labeling appears aimed at defending against patent infringement claims brought by Amgen, legal experts say.

Biosimilars Intellectual Property

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Sandoz's request that US FDA remove psoriatic arthritis and plaque psoriasis indications from biosimilar's approved labeling appears aimed at defending against patent infringement claims brought by Amgen, legal experts say.

Biosimilars Intellectual Property
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Edward V Fritzky, Chmn., Pres. & CEO
    David Mann, CFO
    Deborah Helleson, VP, Bus. Dev.
    Scott Burton, VP, Sales
  • Contact Info
  • Immunex Corp.
    Phone: (206) 587-0430
    51 University St.
    Seattle, WA 98101
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register